Showing results (111-120 of 129) with videos related to
Sort By:
Pageof 13
Therapeutic Advances in Medical Oncology|April 18, 2022
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesJingshan Ho, Valerie Heong, Wei Peng Yong, et al.Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.Lung Cancer (Amsterdam, Netherlands)|December 14, 2019
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysisAaron C Tan, Gillianne G Y Lai, Gek San Tan, et al.Nature Communications|January 17, 2018
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencingRahul Nahar, Weiwei Zhai, Tong Zhang, et al.Oral Oncology|October 22, 2020
Pairing a prognostic target with potential therapeutic strategy for head and neck cancerSze Min Lek, Ke Li, Qiu Xuan Tan, et al.International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint BlockadeKevin L M Chua, Michael Fehlings, Eugenia L L Yeo, et al.Nature|May 18, 2018
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltratesYannick Simoni, Etienne Becht, Michael Fehlings, et al.The New England Journal of Medicine|September 3, 2020
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.Pageof 13